

# DIAGNOSTICS TO SUPPORT TARGETED VACCINATION IN GAVI 5.0

---

BOARD MEETING

**Lee Hampton**

30 November – 2 December 2021, Virtual Meeting



Reach every child

[www.gavi.org](http://www.gavi.org)


# Gavi Targeted Vaccine Support Programmes Are Important for Health Outcomes and Spending

Vaccine	Recommended Routine Immunization Use in All Areas	Outbreak Response Campaigns	Preventive or Catch-up Campaigns	Estimated Deaths Averted 2021-2025	Forecasted Vaccine costs for 2021-2025 (US\$m)*
Oral Cholera	No	Yes	Yes	Not available	238
Typhoid	No	Yes	Yes	~316k	186
Measles/ Rubella	Yes	Yes	Yes	~1,319k	175
Meningococcal	No	Yes	Yes	~106k	103
YF	No	Yes	Yes	~606k	408
Total				~2,347k	1,110

\* Does not include forecasted vaccination campaign operational costs (US\$ 362 million), Vaccine Investment Strategy vaccine operational costs (US\$ 70 million), Vaccine Introduction Grants (US\$ 43 million) or outbreak response vaccine costs (US\$ 136 million) related to these vaccine support programmes.

# Yellow Fever Diagnostics Initiative Shows Gavi Alliance Can Improve Diagnostic Tools & Capability

- **Gavi Alliance efforts have been key to:**
  - First validated commercial YF test kit, with two more under evaluation
  - Avoiding at least two unnecessary YF outbreak response campaigns
  - Quadrupling of the number of African countries at high risk of YF outbreaks able to confirm at least some YF cases on their own
  - Reduced time to confirm YF samples positive at national laboratories



# Bridging Current Gaps in Diagnostic Tools Can Lead to Smarter Spending and Cost Savings

Disease	Potential Benefit
Cholera	Cut in half estimated number of needed preventive cholera campaigns
Typhoid	Realise estimated US\$ 95 to US\$ 193 million value from better matching of typhoid vaccine to areas with typhoid burden
Meningococcus	Substantially improve equity against disease from targeting multivalent meningococcal conjugate vaccine at <50% of African population eligible for meningococcal A conjugate vaccine
Measles / Rubella	Accelerate shift to targeted subnational preventive measles campaigns

# Requested Funding to Improve Availability of Fit-for-Purpose Diagnostic Tools During Gavi 5.0

## Illustrative Forecast of Diagnostic Costs by Disease for 2022-2025

Disease	Diagnostic Procurement (US\$m)	Partner Engagement Framework (US\$m)	Gavi Sect. (US\$m)
Cholera	7	6	2
Meningococcus	5	3	
Measles	4	1	
Rubella	4	1	
Typhoid	7	6	
Yellow Fever	5	4	
<b>Total*</b>	<b>32</b>	<b>21</b>	<b>2</b>

\*Total US\$ 55 million is 3% of forecasted US\$ 1.6 billion costs of the non-diagnostic components of the relevant targeted vaccine support programmes

# Recommendation (1/3)

---

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** an amount of up to US\$ 5 million during 2022-2025 for costs related to the procurement and distribution of diagnostic test kits, reagents, supplies, and equipment for yellow fever in countries eligible for Gavi new vaccine support through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes;
- b) **Approve** an amount of up to US\$ 27 million during 2022-2025 for costs related to the procurement and distribution of diagnostic test kits, reagents, supplies, and equipment for cholera, typhoid, meningococcus, measles, and rubella in countries eligible for Gavi new vaccine support through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes;

## Recommendation (2/3)

---

- c) **Approve** the additional provision of up to US\$ 4 million in funds through the Partners' Engagement Framework (PEF) during 2022-2025, to support global and regional efforts on yellow fever diagnostic capacity strengthening;
- d) **Approve** the additional provision of up to US\$ 17 million in funds through the Partners' Engagement Framework (PEF) during 2022-2025, to support diagnostic test validation, guidance development, multi-country technical assistance, and quality assurance to support effective, efficient, and equitable use of Gavi supported vaccines in countries eligible for Gavi new vaccine support as well as up to US\$ 2 million for Gavi secretariat coordination, monitoring, and operation of Gavi's application, review, and approval processes related to diagnostic tools procurement support during 2022-2025;

## Recommendation (3/3)

---

- e) **Note** the continued use of Health Systems Strengthening (HSS) and Targeted County Assistance (TCA) funds to support surveillance and laboratory capacity in the context of national plans that focus on achieving and maintaining high immunisation coverage and address underlying equity challenges;
- f) **Note** the potential inclusion of assessments of disease-specific diagnostic needs in planning of future Gavi vaccine support proposals to the Board, and potential inclusion of recommendations on addressing disease-specific diagnostic needs in these funding proposals; and
- g) **Request** the Gavi Secretariat to report back to the PPC and Board on progress in 2024.



# Thank You

---



[www.gavi.org](http://www.gavi.org)